Back to Search
Start Over
Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis
- Source :
- Pharmacological Research, Pharmacological Research, Elsevier, 2018, 132, pp.108-118. ⟨10.1016/j.phrs.2018.04.007⟩
- Publication Year :
- 2018
- Publisher :
- HAL CCSD, 2018.
-
Abstract
- BACKGROUND: Approved in 2006, human papillomavirus (HPV) vaccines were initially targeted for girls aged 9-14 years. Although the safety of these vaccines has been monitored through post-licensure surveillance programmes, cases of neurological events have been reported worldwide. PURPOSE: The present study aimed to assess the risk of developing demyelination after HPV immunization by meta-analysing risk estimates from pharmacoepidemiologic studies. DATA SOURCES: A systematic review was conducted in Medline, Embase, ISI Web of Science and the Cochrane Library from inception to 10 May 2017, without language restriction. STUDY SELECTION: Only observational studies including a control group were retained. Study selection was performed by two independent reviewers with disagreements solved through discussion. DATA EXTRACTION: This meta-analysis was performed using a generic inverse variance random-effect model. Outcomes of interest included a broad category of central demyelination, multiple sclerosis (MS), optic neuritis (ON), and Guillain-Barre syndrome (GBS), each being considered independently. Heterogeneity was investigated; sensitivity and subgroup analyses were performed when necessary. In parallel, post-licensure safety studies were considered for a qualitative review. This study followed the PRISMA statement and the MOOSE reporting guideline. DATA SYNTHESIS: Of the 2863 references identified, 11 articles were selected for meta-analysis. No significant association emerged between HPV vaccination and central demyelination, the pooled odds ratio being 0.96 [95%CI 0.77-1.20], with a moderate but non-significant heterogeneity (I(2)=29%). Similar results were found for MS and ON. Sensitivity analyses did not alter our conclusions. Findings from qualitative review of 14 safety studies concluded in an absence of a relevant signal. LIMITATIONS: Owing to limited data on GBS, no meta-analysis was performed for this outcome. CONCLUSION: This study strongly supports the absence of association between HPV vaccines and central demyelination.
- Subjects :
- Risk
medicine.medical_specialty
HPV
MEDLINE
HPV vaccines
Cochrane Library
Human papillomavirus vaccine
03 medical and health sciences
Papillomavirus Vaccines
0302 clinical medicine
Internal medicine
medicine
Humans
Optic neuritis
Multiple sclerosi
030212 general & internal medicine
Pharmacology
PharmacoEpi-Drugs
business.industry
Odds ratio
medicine.disease
3. Good health
Meta-analysis
Observational study
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Demyelination
business
030217 neurology & neurosurgery
Demyelinating Diseases
Subjects
Details
- Language :
- English
- ISSN :
- 10436618 and 10961186
- Database :
- OpenAIRE
- Journal :
- Pharmacological Research, Pharmacological Research, Elsevier, 2018, 132, pp.108-118. ⟨10.1016/j.phrs.2018.04.007⟩
- Accession number :
- edsair.doi.dedup.....21b2f199d84884121a3fb3f1b6f34bfd
- Full Text :
- https://doi.org/10.1016/j.phrs.2018.04.007⟩